A nine-lab network evaluated four Bundibugyo virus PCR assays from two manufacturers in two weeks during the 2026 outbreak, establishing new reference standards, according to a study in The Lancet Infectious Diseases.
Roche has launched two new research PCR assays for Cyclospora cayetanensis detection, expanding lab testing options amid a US outbreak and adding flexibility for gastrointestinal pathogen research.
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
Roche has developed a rapid PCR assay for the rare Ebola Bundibugyo virus, enabling research-use detection within six days to support outbreak response in Central and East Africa, according to the company.
The system simultaneously detects RSV, influenza A and B, and SARS-CoV-2 from a nasal swab in under 10 minutes.
The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.
A randomized trial found Cepheid’s Xpert Xpress MVP test improved appropriate treatment rates for vaginitis within 24 hours compared to standard diagnostic methods.